Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AdC68 Expressing PSA/PSMA/PSCA Vaccine PF-06755992

A prime cancer vaccine comprised of a genetically engineered, replication-deficient chimpanzee adenovirus serotype-68 (AdC68) encoding the tumor-associated antigens (TAAs) human prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA), with potential immunostimulating and antineoplastic activities. Upon administration of AdC68 expressing PSA/PSMA/PSCA priming vaccine PF-06755992, the adenovirus infects and expresses PSA, PSMA and PSCA. The expressed proteins may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing PSA, PSMA and PSCA, thereby inducing tumor cell lysis. PSA, PSMA and PSCA are overexpressed on a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Chimpanzee Adenovirus Serotype-68 Expressing PSA/PSMA/PSCA Priming Vaccine PF-06755992
Chimpanzee adenovirus serotype-68-expressing PSA/PSMA/PSCA priming vaccine PF-06755992
Code name:PF 06755992
PF-06755992
PF06755992
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search